Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62. doi:10.1093/neuonc/nov18926511214
   PubMed Web of Science ®Google Scholar
• Onizuka H, Masui K, Komori T. Diffuse gliomas to date and beyond 2016 WHO classification of tumours of the central nervous system. Int J Clin Oncol. 2020;25(6):997–1003. doi:10.1007/s10147-020-01695-w32468200
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-127157931
   PubMed Web of Science ®Google Scholar
• Akagi Y, Yoshimoto K, Hata N, et al. Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. Brain Tumor Pathol. 2018;35(2):81–89. doi:10.1007/s10014-018-0313-429569163
   PubMed Web of Science ®Google Scholar
• Ebrahimi A, Skardelly M, Bonzheim I, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathol Commun. 2016;4(1):60. doi:10.1186/s40478-016-0331-627311324
   PubMed Web of Science ®Google Scholar
• Zheng L, Zhang M, Hou J, et al. High-grade gliomas with isocitrate dehydrogenase wild-type and 1p/19q codeleted: atypical molecular phenotype and current challenges in molecular diagnosis. Neuropathology. 2020;40(6):599–605. doi:10.1111/neup.1267232761642
   PubMed Web of Science ®Google Scholar
• Ghidini M, Petrelli F, Hahne JC, et al. Clinical outcome and molecular characterization of brain metastases from esophageal and gastric cancer: a systematic review. Med Oncol. 2017;34(4):62. doi:10.1007/s12032-017-0919-028315230
   PubMed Web of Science ®Google Scholar
• Ducray F, Idbaih A, Wang XW, et al. Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther. 2011;11(5):781–789. doi:10.1586/era.10.20221554053
   PubMed Web of Science ®Google Scholar
• Cho HJ, Zhao J, Jung SW, et al. Distinct genomic profile and specific targeted drug responses in adult cerebellar glioblastoma. Neuro Oncol. 2019;21(1):47–58. doi:10.1093/neuonc/noy12330085274
   PubMed Web of Science ®Google Scholar
• Appin CL, Brat DJ. Biomarker-driven diagnosis of diffuse gliomas. Mol Aspects Med. 2015;45:87–96. doi:10.1016/j.mam.2015.05.00226004297
   PubMed Web of Science ®Google Scholar
• Cantero D, Mollejo M, Sepulveda JM, et al. TP53, ATRX alterations, and low tumor mutation load feature IDH-wildtype giant cell glioblastoma despite exceptional ultra-mutated tumors. Neurooncol Adv. 2020;2(1):vdz059. doi:10.1093/noajnl/vdz05932642724
   PubMedGoogle Scholar
• Barritault M, Meyronet D, Ducray F. Molecular classification of adult gliomas: recent advances and future perspectives. Curr Opin Oncol. 2018;30(6):375–382. doi:10.1097/CCO.000000000000048230148717
   PubMed Web of Science ®Google Scholar
• Parker NR, Khong P, Parkinson JF, et al. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol. 2015;5:55. doi:10.3389/fonc.2015.0005525785247
   PubMed Web of Science ®Google Scholar
• Ene CI, Holland EC. Personalized medicine for gliomas. Surg Neurol Int. 2015;6(Suppl1):S89–95. doi:10.4103/2152-7806.15135125722938
   PubMedGoogle Scholar
• Parilla M, Kadri S, Patil SA, et al. Integrating a large next-generation sequencing panel into the clinical diagnosis of gliomas provides a comprehensive platform for classification from FFPE tissue or smear preparations. J Neuropathol Exp Neurol. 2019;78(3):257–267. doi:10.1093/jnen/nly13030698790
   PubMed Web of Science ®Google Scholar
• Nikiforova MN, Wald AI, Melan MA, et al. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors. Neuro Oncol. 2016;18(3):379–387. doi:10.1093/neuonc/nov28926681766
   PubMed Web of Science ®Google Scholar
• Movassaghi M, Shabihkhani M, Hojat SA, et al. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Exp Mol Pathol. 2017;103(1):87–93. doi:10.1016/j.yexmp.2017.06.00628663030
   PubMed Web of Science ®Google Scholar
• Li J, Lupat R, Amarasinghe KC, et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics. 2012;28(10):1307–1313. doi:10.1093/bioinformatics/bts14622474122
   PubMed Web of Science ®Google Scholar
• Boeva V, Popova T, Bleakley K, et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28(3):423–425. doi:10.1093/bioinformatics/btr67022155870
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508. doi:10.1056/NEJMoa140727926061753
   PubMed Web of Science ®Google Scholar
• Jonsson P, Lin AL, Young RJ, et al. Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin Cancer Res. 2019;25(18):5537–5547. doi:10.1158/1078-0432.Ccr-19-003231263031
   PubMed Web of Science ®Google Scholar
• Okamoto I, Sakai K, Morita S, et al. Multiplex genomic profiling of non-small cell lung cancers from the LETS Phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan oncology group study. Oncotarget. 2014;5(8):2293–2304. doi:10.18632/oncotarget.190624810493
   PubMedGoogle Scholar
• Szerlip NJ, Pedraza A, Chakravarty D, et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A. 2012;109(8):3041–3046. doi:10.1073/pnas.111403310922323597
   PubMed Web of Science ®Google Scholar
• Munoz-Hidalgo L, San-Miguel T, Megias J, et al. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma. Neoplasia. 2020;22(1):10–21. doi:10.1016/j.neo.2019.09.00131751860
   PubMed Web of Science ®Google Scholar
• Brito C, Azevedo A, Esteves S, et al. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. BMC Cancer. 2019;19(1):968. doi:10.1186/s12885-019-6177-031623593
   PubMed Web of Science ®Google Scholar
• Liu B, Morrison CD, Johnson CS, et al. Computational methods for detecting copy number variations in cancer genome using next generation sequencing: principles and challenges. Oncotarget. 2013;4(11):1868–1881. doi:10.18632/oncotarget.153724240121
   PubMedGoogle Scholar
• Shao X, Lv N, Liao J, et al. Copy number variation is highly correlated with differential gene expression: a pan-cancer study. BMC Med Genet. 2019;20(1):175. doi:10.1186/s12881-019-0909-531706287
   PubMed Web of Science ®Google Scholar
• Mirchia K, Sathe AA, Walker JM, et al. Total copy number variation as a prognostic factor in adult astrocytoma subtypes. Acta Neuropathol Commun. 2019;7(1):92. doi:10.1186/s40478-019-0746-y31177992
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu Z, Li J, et al. Genomic analysis of primary and recurrent gliomas reveals clinical outcome related molecular features. Sci Rep. 2019;9(1):16058. doi:10.1038/s41598-019-52515-931690770
   PubMed Web of Science ®Google Scholar
• Berzero G, Di Stefano AL, Ronchi S, et al. IDH-wildtype lower grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 2020. doi:10.1093/neuonc/noaa258
   PubMed Web of Science ®Google Scholar
• Crespo I, Vital AL, Nieto AB, et al. Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays. J Mol Diagn. 2011;13(6):634–647. doi:10.1016/j.jmoldx.2011.06.00321884817
   PubMed Web of Science ®Google Scholar
• Blumcke I, Aronica E, Becker A, et al. Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. Nat Rev Neurol. 2016;12(12):732–740. doi:10.1038/nrneurol.2016.17327857123
   PubMed Web of Science ®Google Scholar
• Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, et al. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14(7):434–452. doi:10.1038/nrclinonc.2016.20428031556
   PubMed Web of Science ®Google Scholar
• Cai J, Zhang C, Zhang W, et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience. 2016;3(7–8):258–265. doi:10.18632/oncoscience.31727713914
   PubMedGoogle Scholar
• Jha P, Sarkar C, Pathak P, et al. Detection of allelic status of 1p and 19q by microsatellite-based PCR versus FISH: limitations and advantages in application to patient management. Diagn Mol Pathol. 2011;20(1):40–47. doi:10.1097/PDM.0b013e3181e961e921326038
   PubMedGoogle Scholar
• Silantyev AS, Falzone L, Libra M, et al. Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics. Cells. 2019;8(8):863. doi:10.3390/cells8080863
   PubMed Web of Science ®Google Scholar
• Carter JH, McNulty SN, Cimino PJ, et al. Targeted next-generation sequencing in molecular subtyping of lower-grade diffuse gliomas: application of the world health organization’s 2016 revised criteria for central nervous system tumors. J Mol Diagn. 2017;19(2):328–337. doi:10.1016/j.jmoldx.2016.10.01028042970
   PubMed Web of Science ®Google Scholar
• Cantero D, Rodriguez de Lope A, Moreno de la Presa R, et al. Molecular study of long-term survivors of glioblastoma by gene-targeted next-generation sequencing. J Neuropathol Exp Neurol. 2018;77(8):710–716. doi:10.1093/jnen/nly04830010995
   PubMed Web of Science ®Google Scholar
• Shin H, Sa JK, Bae JS, et al. Clinical targeted next-generation sequencing panels for detection of somatic variants in gliomas. Cancer Res Treat. 2020;52(1):41–50. doi:10.4143/crt.2019.03631096737
   PubMed Web of Science ®Google Scholar
• Geurts M, van den Bent MJ. On high-risk, low-grade glioma: what distinguishes high from low? Cancer. 2019;125(2):174–176. doi:10.1002/cncr.3183430512190
   PubMed Web of Science ®Google Scholar
• Esparragosa I, Diez-Valle R, Tejada S, et al. Management of diffuse glioma. Presse Med. 2018;47(11–12Pt2):e199–e212. doi:10.1016/j.lpm.2018.04.01430385181
   PubMed Web of Science ®Google Scholar
• Iorgulescu JB, Torre M, Harary M, et al. The misclassification of diffuse gliomas: rates and outcomes. Clin Cancer Res. 2019;25(8):2656–2663. doi:10.1158/1078-0432.CCR-18-310130635340
   PubMed Web of Science ®Google Scholar
• Moller RS, Hammer TB, Rubboli G, et al. From next-generation sequencing to targeted treatment of non-acquired epilepsies. Expert Rev Mol Diagn. 2019;19(3):217–228. doi:10.1080/14737159.2019.157314430661434
   PubMed Web of Science ®Google Scholar
• Na K, Kim HS, Shim HS, et al. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol. 2019;142(3):445–454. doi:10.1007/s11060-019-03114-130710203
   PubMed Web of Science ®Google Scholar
• Zacher A, Kaulich K, Stepanow S, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene panel. Brain Pathol. 2017;27(2):146–159. doi:10.1111/bpa.1236726919320
   PubMed Web of Science ®Google Scholar
• Ballester LY, Fuller GN, Powell SZ, et al. Retrospective analysis of molecular and immunohistochemical characterization of 381 primary brain tumors. J Neuropathol Exp Neurol. 2017;76(3):179–188. doi:10.1093/jnen/nlw11928395087
   PubMed Web of Science ®Google Scholar
• Sahm F, Schrimpf D, Jones DT, et al. Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol. 2016;131(6):903–910. doi:10.1007/s00401-015-1519-826671409
   PubMed Web of Science ®Google Scholar
• Vaubel RA, Tian S, Remonde D, et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 2020;26(5):1094–1104. doi:10.1158/1078-0432.CCR-19-090931852831
   PubMed Web of Science ®Google Scholar
• Baldock AL, Yagle K, Born DE, et al. Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status. Neuro Oncol. 2014;16(6):779–786. doi:10.1093/neuonc/nou02724832620
   PubMed Web of Science ®Google Scholar
• Miyata S, Tominaga K, Sakashita E, et al. Comprehensive metabolomic analysis of IDH1(R132H) clinical glioma samples reveals suppression of beta-oxidation due to carnitine deficiency. Sci Rep. 2019;9(1):9787. doi:10.1038/s41598-019-46217-531278288
   PubMed Web of Science ®Google Scholar
• Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, Phase 2 trial. Lancet Oncol. 2019;20(1):110–119. doi:10.1016/S1470-2045(18)30675-230522967
   PubMed Web of Science ®Google Scholar
• Indraccolo S, De Salvo GL, Verza M, et al. Phosphorylated Acetyl-CoA carboxylase is associated with clinical benefit with regorafenib in relapsed glioblastoma: REGOMA trial biomarker analysis. Clin Cancer Res. 2020;26(17):4478–4484. doi:10.1158/1078-0432.CCR-19-405532518098
   PubMed Web of Science ®Google Scholar
• Santangelo A, Rossato M, Lombardi G, et al. A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib. Neuro Oncol. 2020. doi:10.1093/neuonc/noaa156
   Web of Science ®Google Scholar
• Reis GF, Pekmezci M, Hansen HM, et al. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II–III) astrocytomas. J Neuropathol Exp Neurol. 2015;74(5):442–452. doi:10.1097/NEN.000000000000018825853694
   PubMed Web of Science ®Google Scholar